{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:24:20Z","timestamp":1789176260314,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s11916-023-01126-1","type":"journal-article","created":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T10:02:00Z","timestamp":1688205720000},"page":"299-305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A Brief Review on the Novel Therapies for Painful Diabetic Neuropathy"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7506-547X","authenticated-orcid":false,"given":"Jade I.","family":"Basem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatoumata N.","family":"Bah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel D.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,1]]},"reference":[{"issue":"3","key":"1126_CR1","doi-asserted-by":"publisher","first-page":"432","DOI":"10.4239\/wjd.v6.i3.432","volume":"6","author":"AK Schreiber","year":"2015","unstructured":"Schreiber AK, Nones CF, Reis RC, Chichorro JG, Cunha JM. Diabetic neuropathic pain: physiopathology and treatment. World J Diabetes. 2015;6(3):432\u201344.","journal-title":"World J Diabetes"},{"key":"1126_CR2","doi-asserted-by":"crossref","unstructured":"Gupta M, Knezevic NN, Abd-Elsayed A, Ray M, Patel K, Chowdhury B, et al. Treatment of painful diabetic neuropathy-a narrative review of pharmacological and interventional approaches. Biomedicines. 2021;9(5).","DOI":"10.3390\/biomedicines9050573"},{"key":"1126_CR3","doi-asserted-by":"publisher","first-page":"9989272","DOI":"10.1155\/2022\/9989272","volume":"2022","author":"Z Qureshi","year":"2022","unstructured":"Qureshi Z, Ali MN, Khalid M. An insight into potential pharmacotherapeutic agents for painful diabetic neuropathy. J Diabetes Res. 2022;2022:9989272.","journal-title":"J Diabetes Res"},{"issue":"1","key":"1126_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s13300-018-0550-x","volume":"10","author":"S Azmi","year":"2019","unstructured":"Azmi S, ElHadd KT, Nelson A, Chapman A, Bowling FL, Perumbalath A, et al. Pregabalin in the management of painful diabetic neuropathy: a narrative review. Diabetes Ther. 2019;10(1):35\u201356.","journal-title":"Diabetes Ther"},{"issue":"16","key":"1126_CR5","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1080\/14656566.2021.1909570","volume":"22","author":"K Pafili","year":"2021","unstructured":"Pafili K, Papanas N. Considerations for single- versus multiple-drug pharmacotherapy in the management of painful diabetic neuropathy. Expert Opin Pharmacother. 2021;22(16):2267\u201380.","journal-title":"Expert Opin Pharmacother"},{"key":"1126_CR6","doi-asserted-by":"crossref","unstructured":"Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA, et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019;1(1):Cd007076.","DOI":"10.1002\/14651858.CD007076.pub3"},{"key":"1126_CR7","doi-asserted-by":"crossref","unstructured":"Wiffen PJ, Derry S, Bell RF, Rice AS, T\u00f6lle TR, Phillips T, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6(6):Cd007938.","DOI":"10.1002\/14651858.CD003726.pub4"},{"issue":"1","key":"1126_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/2049463712438493","volume":"6","author":"H Pathan","year":"2012","unstructured":"Pathan H, Williams J. Basic opioid pharmacology: an update. Br J Pain. 2012;6(1):11\u20136.","journal-title":"Br J Pain"},{"issue":"3","key":"1126_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11916-020-00934-z","volume":"25","author":"SC Erosa","year":"2021","unstructured":"Erosa SC, Haffey PR, Mehta N, Gulati A. Tapentadol, buprenorphine, and levorphanol for the treatment of neuropathic pain: a systematic review. Curr Pain Headache Rep. 2021;25(3):18.","journal-title":"Curr Pain Headache Rep"},{"issue":"1","key":"1126_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1185\/03007995.2010.537589","volume":"27","author":"S Schwartz","year":"2011","unstructured":"Schwartz S, Etropolski M, Shapiro DY, Okamoto A, Lange R, Haeussler J, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27(1):151\u201362.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"1126_CR11","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.2337\/dc13-2291","volume":"37","author":"AI Vinik","year":"2014","unstructured":"Vinik AI, Shapiro DY, Rauschkolb C, Lange B, Karcher K, Pennett D, et al. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Diabetes Care. 2014;37(8):2302\u20139.","journal-title":"Diabetes Care"},{"issue":"2","key":"1126_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1213\/ANE.0000000000002718","volume":"127","author":"R Aiyer","year":"2018","unstructured":"Aiyer R, Gulati A, Gungor S, Bhatia A, Mehta N. Treatment of chronic pain with various buprenorphine formulations: a systematic review of clinical studies. Anesth Analg. 2018;127(2):529\u201338.","journal-title":"Anesth Analg"},{"issue":"9","key":"1126_CR13","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.2337\/dc16-0123","volume":"39","author":"RW Simpson","year":"2016","unstructured":"Simpson RW, Wlodarczyk JH. Transdermal buprenorphine relieves neuropathic pain: a randomized, double-blind, parallel-group, placebo-controlled trial in diabetic peripheral neuropathic pain. Diabetes Care. 2016;39(9):1493\u2013500.","journal-title":"Diabetes Care"},{"issue":"8","key":"1126_CR14","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1212\/01.wnl.0000240225.04000.1a","volume":"67","author":"JF Wernicke","year":"2006","unstructured":"Wernicke JF, Pritchett YL, D\u2019Souza DN, Waninger A, Tran P, Iyengar S, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67(8):1411\u201320.","journal-title":"Neurology"},{"issue":"20","key":"1126_CR15","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1212\/WNL.0b013e3182166ebe","volume":"76","author":"V Bril","year":"2011","unstructured":"Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76(20):1758\u201365.","journal-title":"Neurology"},{"key":"1126_CR16","doi-asserted-by":"crossref","unstructured":"Ardeleanu V, Toma A, Pafili K, Papanas N, Motofei I, Diaconu CC, et al. Current pharmacological treatment of painful diabetic neuropathy: a narrative review. Medicina (Kaunas). 2020;56(1).","DOI":"10.3390\/medicina56010025"},{"issue":"2","key":"1126_CR17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4103\/jmau.jmau_97_20","volume":"10","author":"AM Bagher","year":"2022","unstructured":"Bagher AM. The Endocannabinoid system as a therapeutic target in diabetic peripheral neuropathic pain: a review. J Microsc Ultrastruct. 2022;10(2):47\u201354.","journal-title":"J Microsc Ultrastruct"},{"issue":"7","key":"1126_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2020.165771","volume":"1866","author":"ZH Maayah","year":"2020","unstructured":"Maayah ZH, Takahara S, Ferdaoussi M, Dyck JRB. The molecular mechanisms that underpin the biological benefits of full-spectrum cannabis extract in the treatment of neuropathic pain and inflammation. Biochim Biophys Acta Mol Basis Dis. 2020;1866(7):165771.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"4","key":"1126_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/ACO.0000000000000616","volume":"31","author":"B Bie","year":"2018","unstructured":"Bie B, Wu J, Foss JF, Naguib M. An overview of the cannabinoid type 2 receptor system and its therapeutic potential. Curr Opin Anaesthesiol. 2018;31(4):407\u201314.","journal-title":"Curr Opin Anaesthesiol"},{"key":"1126_CR20","doi-asserted-by":"crossref","unstructured":"Quintero JM, Pulido G, Giraldo LF, Leon MX, Diaz LE, Bustos RH, et al. A systematic review on cannabinoids for neuropathic pain administered by routes other than oral or inhalation. Plants (Basel). 2022;11(10).","DOI":"10.3390\/plants11101357"},{"issue":"6","key":"1126_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.17245\/jdapm.2021.21.6.479","volume":"21","author":"B Sainsbury","year":"2021","unstructured":"Sainsbury B, Bloxham J, Pour MH, Padilla M, Enciso R. Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta-analysis. J Dent Anesth Pain Med. 2021;21(6):479\u2013506.","journal-title":"J Dent Anesth Pain Med"},{"issue":"Suppl 1","key":"1126_CR22","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.1097\/j.pain.0000000000001941","volume":"162","author":"RA Moore","year":"2021","unstructured":"Moore RA, Fisher E, Finn DP, Finnerup NB, Gilron I, Haroutounian S, et al. Cannabinoids, cannabis, and cannabis-based medicines for pain management: an overview of systematic reviews. Pain. 2021;162(Suppl 1):S67-s79.","journal-title":"Pain"},{"issue":"5","key":"1126_CR23","doi-asserted-by":"publisher","first-page":"390","DOI":"10.2174\/1389201020666191202111534","volume":"21","author":"DH Xu","year":"2020","unstructured":"Xu DH, Cullen BD, Tang M, Fang Y. The effectiveness of topical cannabidiol oil in symptomatic relief of peripheral neuropathy of the lower extremities. Curr Pharm Biotechnol. 2020;21(5):390\u2013402.","journal-title":"Curr Pharm Biotechnol"},{"key":"1126_CR24","doi-asserted-by":"crossref","unstructured":"M\u00fccke M, Phillips T, Radbruch L, Petzke F, H\u00e4user W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3(3):Cd012182.","DOI":"10.1002\/14651858.CD012182.pub2"},{"issue":"7","key":"1126_CR25","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jpain.2015.03.008","volume":"16","author":"MS Wallace","year":"2015","unstructured":"Wallace MS, Marcotte TD, Umlauf A, Gouaux B, Atkinson JH. Efficacy of inhaled cannabis on painful diabetic neuropathy. J Pain. 2015;16(7):616\u201327.","journal-title":"J Pain"},{"issue":"1","key":"1126_CR26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.2337\/dc09-1029","volume":"33","author":"D Selvarajah","year":"2010","unstructured":"Selvarajah D, Gandhi R, Emery CJ, Tesfaye S. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care. 2010;33(1):128\u201330.","journal-title":"Diabetes Care"},{"key":"1126_CR27","doi-asserted-by":"crossref","unstructured":"D'Amico R, Impellizzeri D, Cuzzocrea S, Di Paola R. ALIAmides update: Palmitoylethanolamide and its formulations on management of peripheral neuropathic pain. Int J Mol Sci. 2020;21(15).","DOI":"10.3390\/ijms21155330"},{"key":"1126_CR28","doi-asserted-by":"crossref","unstructured":"Petrosino S, Schiano Moriello A. Palmitoylethanolamide: a nutritional approach to keep neuroinflammation within physiological boundaries-a systematic review. Int J Mol Sci. 2020;21(24).","DOI":"10.3390\/ijms21249526"},{"key":"1126_CR29","volume":"2014","author":"C Schifilliti","year":"2014","unstructured":"Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C, et al. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623.","journal-title":"Pain Res Treat"},{"issue":"2","key":"1126_CR30","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s12020-019-01917-w","volume":"66","author":"S Pieralice","year":"2019","unstructured":"Pieralice S, Vari R, Minutolo A, Maurizi AR, Fioriti E, Napoli N, et al. Biomarkers of response to alpha-lipoic acid \u00b1 palmitoiletanolamide treatment in patients with diabetes and symptoms of peripheral neuropathy. Endocrine. 2019;66(2):178\u201384.","journal-title":"Endocrine"},{"issue":"5","key":"1126_CR31","doi-asserted-by":"publisher","first-page":"561","DOI":"10.4097\/kjae.2017.70.5.561","volume":"70","author":"TK Seol","year":"2017","unstructured":"Seol TK, Lee W, Park S, Kim KN, Kim TY, Oh YN, et al. Effect of palmitoylethanolamide on inflammatory and neuropathic pain in rats. Korean J Anesthesiol. 2017;70(5):561\u20136.","journal-title":"Korean J Anesthesiol"},{"issue":"5","key":"1126_CR32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/ddr.21259","volume":"76","author":"M D\u00e9ciga-Campos","year":"2015","unstructured":"D\u00e9ciga-Campos M, Ort\u00edz-Andrade R. Enhancement of antihyperalgesia by the coadministration of n-palmitoylethanolamide and acetaminophen in diabetic rats. Drug Dev Res. 2015;76(5):228\u201334.","journal-title":"Drug Dev Res"},{"issue":"4","key":"1126_CR33","doi-asserted-by":"publisher","first-page":"452","DOI":"10.2174\/1871527314666150429111537","volume":"14","author":"G Donvito","year":"2015","unstructured":"Donvito G, Bettoni I, Comelli F, Colombo A, Costa B. Palmitoylethanolamide relieves pain and preserves pancreatic islet cells in a murine model of diabetes. CNS Neurol Disord Drug Targets. 2015;14(4):452\u201362.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"1126_CR34","unstructured":"Eliem Therapeutics Provides ETX-810 Program Update [press release]. August 2, 2022. Available at:\u00a0https:\/\/ir.eliemtx.com\/news-releases\/news-release-details\/eliem-provides-update-etx-810-and-etx-155-clinical-programs. Accessed 3 Apr 2023."},{"issue":"1","key":"1126_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jpain.2016.09.008","volume":"18","author":"DM Simpson","year":"2017","unstructured":"Simpson DM, Robinson-Papp J, Van J, Stoker M, Jacobs H, Snijder RJ, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled Study. J Pain. 2017;18(1):42\u201353.","journal-title":"J Pain"},{"issue":"1","key":"1126_CR36","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12883-016-0752-7","volume":"16","author":"AI Vinik","year":"2016","unstructured":"Vinik AI, Perrot S, Vinik EJ, Pazdera L, Jacobs H, Stoker M, et al. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. BMC Neurol. 2016;16(1):251.","journal-title":"BMC Neurol"},{"issue":"5","key":"1126_CR37","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2217\/pmt-2021-0025","volume":"12","author":"Y Leavell","year":"2022","unstructured":"Leavell Y, Simpson DM. The role of the capsaicin 8% patch in the treatment of painful diabetic peripheral neuropathy. Pain Manag. 2022;12(5):595\u2013609.","journal-title":"Pain Manag"},{"key":"1126_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113439","volume":"153","author":"PV Dludla","year":"2022","unstructured":"Dludla PV, Nkambule BB, Cirilli I, Marcheggiani F, Mabhida SE, Ziqubu K, et al. Capsaicin, its clinical significance in patients with painful diabetic neuropathy. Biomed Pharmacother. 2022;153:113439.","journal-title":"Biomed Pharmacother"},{"key":"1126_CR39","doi-asserted-by":"crossref","unstructured":"Derry S, Rice AS, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;1(1):Cd007393.","DOI":"10.1002\/14651858.CD007393.pub4"},{"issue":"3","key":"1126_CR40","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/14737175.2021.1874920","volume":"21","author":"RMC Abrams","year":"2021","unstructured":"Abrams RMC, Pedowitz EJ, Simpson DM. A critical review of the capsaicin 8% patch for the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet in adults. Expert Rev Neurother. 2021;21(3):259\u201366.","journal-title":"Expert Rev Neurother"},{"key":"1126_CR41","first-page":"51","volume":"5","author":"C Martini","year":"2012","unstructured":"Martini C, Yassen A, Olofsen E, Passier P, Stoker M, Dahan A, et al. Pharmacodynamic analysis of the analgesic effect of capsaicin 8% patch (Qutenza\u2122) in diabetic neuropathic pain patients: detection of distinct response groups. J Pain Res. 2012;5:51\u20139.","journal-title":"J Pain Res"},{"issue":"4","key":"1126_CR42","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.clinthera.2017.02.010","volume":"39","author":"F van Nooten","year":"2017","unstructured":"van Nooten F, Treur M, Pantiri K, Stoker M, Charokopou M. Capsaicin 8% patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy: a systematic literature review and network meta-analysis. Clin Ther. 2017;39(4):787-803.e18.","journal-title":"Clin Ther"},{"issue":"1","key":"1126_CR43","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40200-021-00741-2","volume":"20","author":"N Hussain","year":"2021","unstructured":"Hussain N, Said ASA, Javaid FA, Al Haddad AHI, Anwar M, Khan Z, et al. The efficacy and safety profile of capsaicin 8% patch versus 5% Lidocaine patch in patients with diabetic peripheral neuropathic pain: a randomized, placebo-controlled study of south Asian male patients. J Diabetes Metab Disord. 2021;20(1):271\u20138.","journal-title":"J Diabetes Metab Disord"},{"issue":"5","key":"1126_CR44","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1097\/AJP.0000000000000547","volume":"34","author":"R Aiyer","year":"2018","unstructured":"Aiyer R, Mehta N, Gungor S, Gulati A. A systematic review of NMDA receptor antagonists for treatment of neuropathic pain in clinical practice. Clin J Pain. 2018;34(5):450\u201367.","journal-title":"Clin J Pain"},{"issue":"2","key":"1126_CR45","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/cts.12584","volume":"12","author":"DR Houck","year":"2019","unstructured":"Houck DR, Sindelar L, Sanabria CR, Stanworth SH, Krueger M, Suh M, et al. NYX-2925, A novel n-methyl-d-aspartate receptor modulator: a first-in-human, randomized, double-blind study of safety and pharmacokinetics in adults. Clin Transl Sci. 2019;12(2):164\u201371.","journal-title":"Clin Transl Sci"},{"key":"1126_CR46","unstructured":"Aptinyx reports results from phase 2b study of NYX-2925 in painful diabetic peripheral neuropathy [press release]. Available at: https:\/\/ir.aptinyx.com\/press-releases\/news-details\/2022\/Aptinyx-Reports-Results-from-Phase-2b-Study-of-NYX-2925-in-Painful-Diabetic-Peripheral-Neuropathy\/default.aspx2022. Accessed 3 Apr 2023."},{"issue":"11","key":"1126_CR47","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1016\/j.pain.2014.08.031","volume":"155","author":"CC de Vos","year":"2014","unstructured":"de Vos CC, Meier K, Zaalberg PB, Nijhuis HJ, Duyvendak W, Vesper J, et al. Spinal cord stimulation in patients with painful diabetic neuropathy: a multicentre randomized clinical trial. Pain. 2014;155(11):2426\u201331.","journal-title":"Pain"},{"issue":"2","key":"1126_CR48","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1177\/19322968211060075","volume":"16","author":"NH Strand","year":"2022","unstructured":"Strand NH, Burkey AR. Neuromodulation in the treatment of painful diabetic neuropathy: a review of evidence for spinal cord stimulation. J Diabetes Sci Technol. 2022;16(2):332\u201340.","journal-title":"J Diabetes Sci Technol"},{"issue":"1","key":"1126_CR49","doi-asserted-by":"publisher","first-page":"32","DOI":"10.2337\/dc17-0983","volume":"41","author":"M van Beek","year":"2018","unstructured":"van Beek M, Geurts JW, Slangen R, Schaper NC, Faber CG, Joosten EA, et al. Severity of neuropathy is associated with long-term spinal cord stimulation outcome in painful diabetic peripheral neuropathy: five-year follow-up of a prospective two-center clinical trial. Diabetes Care. 2018;41(1):32\u20138.","journal-title":"Diabetes Care"},{"issue":"4","key":"1126_CR50","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/ejp.1336","volume":"23","author":"MP Jensen","year":"2019","unstructured":"Jensen MP, Brownstone RM. Mechanisms of spinal cord stimulation for the treatment of pain: Still in the dark after 50 years. Eur J Pain. 2019;23(4):652\u20139.","journal-title":"Eur J Pain"},{"issue":"6","key":"1126_CR51","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jamaneurol.2021.0538","volume":"78","author":"EA Petersen","year":"2021","unstructured":"Petersen EA, Stauss TG, Scowcroft JA, Brooks ES, White JL, Sills SM, et al. Effect of high-frequency (10-khz) spinal cord stimulation in patients with painful diabetic neuropathy: a randomized clinical trial. JAMA Neurol. 2021;78(6):687\u201398.","journal-title":"JAMA Neurol"},{"key":"1126_CR52","doi-asserted-by":"crossref","unstructured":"Petersen E, Stauss T, Scowcroft J, Brooks E, White J, Sills S, et al. 22-LB: 24-month results for 10-khz spinal cord stimulation (SCS) in treating painful diabetic neuropathy (PDN). Diabetes. 2022;71.","DOI":"10.2337\/db22-22-LB"},{"issue":"4","key":"1126_CR53","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.mayocpiqo.2022.05.003","volume":"6","author":"EA Petersen","year":"2022","unstructured":"Petersen EA, Stauss TG, Scowcroft JA, Brooks ES, White JL, Sills SM, et al. High-frequency 10-khz spinal cord stimulation improves health-related quality of life in patients with refractory painful diabetic neuropathy: 12-month results from a randomized controlled trial. Mayo Clin Proc Innov Qual Outcomes. 2022;6(4):347\u201360.","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"Suppl 1","key":"1126_CR54","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1093\/pm\/pnz003","volume":"20","author":"T Kirketeig","year":"2019","unstructured":"Kirketeig T, Schultheis C, Zuidema X, Hunter CW, Deer T. Burst spinal cord stimulation: a clinical review. Pain Med. 2019;20(Suppl 1):S31-s40.","journal-title":"Pain Med"},{"issue":"1","key":"1126_CR55","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/ner.12698","volume":"21","author":"T Deer","year":"2018","unstructured":"Deer T, Slavin KV, Amirdelfan K, North RB, Burton AW, Yearwood TL, et al. Success using neuromodulation with BURST (SUNBURST) study: results from a prospective, randomized controlled trial using a novel burst waveform. Neuromodulation. 2018;21(1):56\u201366.","journal-title":"Neuromodulation"},{"issue":"1","key":"1126_CR56","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/ner.13216","volume":"24","author":"ALB Raghu","year":"2021","unstructured":"Raghu ALB, Parker T, Aziz TZ, Green AL, Hadjipavlou G, Rea R, et al. Invasive electrical neuromodulation for the treatment of painful diabetic neuropathy: systematic review and meta-analysis. Neuromodulation. 2021;24(1):13\u201321.","journal-title":"Neuromodulation"},{"issue":"2","key":"1126_CR57","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/ner.12116","volume":"17","author":"CC de Vos","year":"2014","unstructured":"de Vos CC, Bom MJ, Vanneste S, Lenders MW, de Ridder D. Burst spinal cord stimulation evaluated in patients with failed back surgery syndrome and painful diabetic neuropathy. Neuromodulation. 2014;17(2):152\u20139.","journal-title":"Neuromodulation"},{"issue":"8","key":"1126_CR58","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s11916-022-01061-7","volume":"26","author":"RS D'Souza","year":"2022","unstructured":"D\u2019Souza RS, Barman R, Joseph A, Abd-Elsayed A. Evidence-based treatment of painful diabetic neuropathy: a systematic review. Curr Pain Headache Rep. 2022;26(8):583\u201394.","journal-title":"Curr Pain Headache Rep"}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-023-01126-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-023-01126-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-023-01126-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T13:20:40Z","timestamp":1729689640000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-023-01126-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1126"],"URL":"https:\/\/doi.org\/10.1007\/s11916-023-01126-1","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,1]]},"assertion":[{"value":"1 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Neel Mehta has been a consultant to Averitas, and Nevro. He has sponsored research with Nevro in the area of diabetic neuropathy.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}